- Active, not recruiting
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM
Updated: Feb 10
Dara-KRd
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
This study is being done because, despite major advances in therapy, MM is still considered an incurable disease. The purpose of this study is to determine the efficacy (how well it works) of the study treatment that combines the following drugs: daratumumab, carfilzomib, lenalidomide, dexamethasone in subjects who have a recent diagnosis of multiple myeloma (MM).
Sponsor
Collaborators
ClinicalTrials.gov Identifier: NCT04113018
Official Title: LCI-HEM-MYE-KRdD-001: Phase II Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
First Posted : October 2, 2019
Click here for details on ClinicalTrials.gov
* Carfilzomib (Kyprolis)
* Lenalidomide (Revlimid)
* Dexamethasone (Decadron)
* Daratumumab (Darzalex)
Drug: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
- North Carolina: Levine Cancer Institute Charlotte
Locations
United States, North Carolina